Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer

Valentina Piastra,Federica Ganci,Andrea Sacconi,Angelina Pranteda,Matteo Allegretti,Roberta Bernardini,Martina Serra,Barbara Lupo,Emanuela Dell'Aquila,Gianluigi Ferretti,Edoardo Pescarmona,Armando Bartolazzi,Giovanni Blandino,Livio Trusolino and Gianluca Bossi
DOI: https://doi.org/10.1186/s13046-024-03150-4
IF: 12.658
2024-08-22
Journal of Experimental & Clinical Cancer Research
Abstract:Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer-related deaths worldwide, with a survival rate near to 10% when diagnosed at an advanced stage. Hence, the identification of new molecular targets to design more selective and efficient therapies is urgently required. The Mitogen activated protein kinase kinase 3 (MKK3) is a dual-specificity threonine/tyrosine protein kinase that, activated in response to cellular stress and inflammatory stimuli, regulates a plethora of biological processes. Previous studies revealed novel MKK3 roles in supporting tumor malignancy, as its depletion induces autophagy and cell death in cancer lines of different tumor types, including CRC. Therefore, MKK3 may represent an interesting new therapeutic target in advanced CRC, however selective MKK3 inhibitors are currently not available.
oncology
What problem does this paper attempt to address?